Altogether, MCP-1 associated differentially with the tested inflammatory and pulmonary remodeling biomarkers and was found to correlate positively with: (i) IFN-α2, IL-10, fractalkine, and VEGF in T2D patients with asthma; (ii) IL-6 and GRO-α in T2D patients without asthma; (iii) MDC, IP-10, GM-CSF, FGF-2, and PDGF-AA/BB in patients with asthma only; and (iv) FPG and TG in non-diabetic non-asthmatic controls. This evidence concerns the gene CCL22 and type 2 diabetes mellitus.